Berndt, S.I.Wang, Z.Yeager, M.Alavanja, M.C.Albanes, D.Amundadottir, L.Andriole, G.Beane Freeman, L.Campa, D.Cancel-Tassin, G.Canzian, F.Cornu, J.-N.Cussenot, O.Diver, W.R.Gapstur, S.M.Grönberg, H.Haiman, C.A.Henderson, B.Hutchinson, A.Hunter, D.J.Key, T.J.Kolb, S.Koutros, S.Kraft, P.Le Marchand, L.Lindström, S.Machiela, M.J.Ostrander, E.A.Riboli, E.Schumacher, F.Siddiq, A.Stanford, J.L.Stevens, V.L.Travis, R.C.Tsilidis, K.K.Virtamo, J.Weinstein, S.Wilkund, F.Xu, J.Lilly Zheng, S.Yu, K.Wheeler, W.Zhang, H.Sampson, J.Black, A.Jacobs, K.Hoover, R.N.Tucker, M.Chanock, S.J.2018-09-182018-09-182015-05doi: 10.1038/ncomms7889.http://ugspace.ug.edu.gh/handle/123456789/24244Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.enlociprostate cancerindolent diseasegenetictreatmentGleason scoreArticle